For those who do not remember SKYCLARYS is Reata's drug for Ataxia Friedreich which was acquired by Biogen for 7.3 Billions USD and which is comparable to the entire DAYBUE package (Neuren + Acadia), our CEO has spoken about it several times in the Webinars, so 102M USD total (including row) and 71M USD in the USA, we await the earnings of Acadia at the end of the month to see where we are in the USA with DAYBUE waiting for approval in Canada and Europe next year
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)